Vitamin B6 and Cancer Risk: A Field Synopsis and Meta-Analysis

Background: Vitamin B6 is involved in many biochemical reactions and might play a role in carcinogenesis. We summarized the evidence linking vitamin B6 to cancer risk.

Methods: We conducted a systematic review of both observational and intervention studies investigating the relationship between vitamin B6 intake or blood levels of its bioactive form pyridoxal-5'-phosphate (PLP) and the risk of any type of cancer. Random-effects meta-analysis was used to calculate pooled relative risks (RRs) and their 95% confidence intervals (CIs) across studies for high vs low categories of vitamin intake or PLP levels. We also performed a random-effects dose-response meta-analysis.

Results: We identified 121 observational studies (participants, n = 1 924 506; cases, n = 96_,436) and nine randomized controlled trials (RCTs; participants, n = 34 911; cases, n = 2539) considering 19 tumor sites. High intake of dietary (food only) vitamin B6 was statistically significantly associated with lower risk of all cancers (relative risk [RR] = 0.78, 95% CI = 0.73 to 0.84) and specific tumors, with special regard to gastrointestinal carcinomas (RR = 0.68, 95% CI = 0.61 to 0.75). An inverse association was also observed between high PLP levels and the risk of all cancers (RR = 0.66, 95% CI = 0.58 to 0.76) and single tumor sites, the most consistent results being those for gastrointestinal tumors (RR = 0.56, 95% CI = 0.48 to 0.65). There was a statistically significant inverse linear relationship between cancer risk and both vitamin B6 dietary intake and PLP levels. When total (food and supplements) intake was considered, the associations were weaker or null. Findings from RCTs did not support a protective effect of vitamin B6 against cancer, although this evidence was graded as low level.

Conclusions: Epidemiological evidence supports the potential of vitamin B6 as a cancer risk reduction agent and the role of PLP as a cancer screening biomarker, especially for gastrointestinal tumors. However, inconsistent findings from total intake and intervention studies suggest that vitamin B6 might also be an indicator of other dietary protective micronutrients.

http://ift.tt/2ecHDpT

Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis

Background: Neurokinin-1 receptor antagonists (NK-1RAs) are widely used for chemotherapy-induced nausea and vomiting (CINV) control in patients with highly emetogenic chemotherapy (HEC) and/or moderately emetogenic chemotherapy (MEC). Whether the efficacy and toxicity of antiemesis are different among various NK-1RA-based triple regimens is unknown.

Methods: Data of complete responses (CRs) in the acute, delayed, and overall phases and treatment-related adverse events (TRAEs) were extracted from electronic databases. Efficacy and toxicity were integrated by pairwise and network meta-analyses.

Results: Thirty-six trials involving 18 889 patients using triple regimens (NK-1RA+serotonin receptor antagonists [5HT3RA] + dexamethasone) or duplex regimen (5HT3RA+dexamethasone) to control CINV were included in the analysis. Different NK-1RA-based triple regimens shared equivalent effect on CRs. In patients with HEC, almost all triple regimens showed statistically significantly higher CRs than duplex regimen (odds ratio [OR]_{duplex/triple} = 0.47–0.66). However, in patients with MEC, only aprepitant-based triple regimen showed better effect than duplex regimen statistically significantly in CRs (OR_{duplex/triple} = 0.52, 95% confidence interval [CI] = 0.34 to 0.68). No statistically significant difference of TRAEs was found among different triple regimens. Palonosetron-based triple regimens were equivalent to first-generation 5HT3RAs-based triple regimens for CRs. Moreover, different doses of dexamethasone plus NK-1RA and 5HT3RA showed no statistically significant difference in CRs.

Conclusions: Different NK-1RAs-based triple regimens shared equivalent effect on CINV control. Various triple regimens had superior antiemetic effect than duplex regimen in patients with HEC. Only aprepitant-based triple regimen showed better CINV control compared with duplex regimen in patients receiving MEC. Palonosetron and first-generation 5HT3RAs might share equivalent CINV control in the combination of NK-1RAs and dexamethasone. Lower doses of dexamethasone might be applied when used with NK-1RAs and 5HT3RAs.

http://ift.tt/2f7jP4q

Vitamin B6 and Cancer Risk: A Field Synopsis and Meta-Analysis

Background: Vitamin B6 is involved in many biochemical reactions and might play a role in carcinogenesis. We summarized the evidence linking vitamin B6 to cancer risk.

Methods: We conducted a systematic review of both observational and intervention studies investigating the relationship between vitamin B6 intake or blood levels of its bioactive form pyridoxal-5'-phosphate (PLP) and the risk of any type of cancer. Random-effects meta-analysis was used to calculate pooled relative risks (RRs) and their 95% confidence intervals (CIs) across studies for high vs low categories of vitamin intake or PLP levels. We also performed a random-effects dose-response meta-analysis.

Results: We identified 121 observational studies (participants, n = 1 924 506; cases, n = 96_,436) and nine randomized controlled trials (RCTs; participants, n = 34 911; cases, n = 2539) considering 19 tumor sites. High intake of dietary (food only) vitamin B6 was statistically significantly associated with lower risk of all cancers (relative risk [RR] = 0.78, 95% CI = 0.73 to 0.84) and specific tumors, with special regard to gastrointestinal carcinomas (RR = 0.68, 95% CI = 0.61 to 0.75). An inverse association was also observed between high PLP levels and the risk of all cancers (RR = 0.66, 95% CI = 0.58 to 0.76) and single tumor sites, the most consistent results being those for gastrointestinal tumors (RR = 0.56, 95% CI = 0.48 to 0.65). There was a statistically significant inverse linear relationship between cancer risk and both vitamin B6 dietary intake and PLP levels. When total (food and supplements) intake was considered, the associations were weaker or null. Findings from RCTs did not support a protective effect of vitamin B6 against cancer, although this evidence was graded as low level.

Conclusions: Epidemiological evidence supports the potential of vitamin B6 as a cancer risk reduction agent and the role of PLP as a cancer screening biomarker, especially for gastrointestinal tumors. However, inconsistent findings from total intake and intervention studies suggest that vitamin B6 might also be an indicator of other dietary protective micronutrients.

http://ift.tt/2ecHDpT

Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis

Background: Neurokinin-1 receptor antagonists (NK-1RAs) are widely used for chemotherapy-induced nausea and vomiting (CINV) control in patients with highly emetogenic chemotherapy (HEC) and/or moderately emetogenic chemotherapy (MEC). Whether the efficacy and toxicity of antiemesis are different among various NK-1RA-based triple regimens is unknown.

Methods: Data of complete responses (CRs) in the acute, delayed, and overall phases and treatment-related adverse events (TRAEs) were extracted from electronic databases. Efficacy and toxicity were integrated by pairwise and network meta-analyses.

Results: Thirty-six trials involving 18 889 patients using triple regimens (NK-1RA+serotonin receptor antagonists [5HT3RA] + dexamethasone) or duplex regimen (5HT3RA+dexamethasone) to control CINV were included in the analysis. Different NK-1RA-based triple regimens shared equivalent effect on CRs. In patients with HEC, almost all triple regimens showed statistically significantly higher CRs than duplex regimen (odds ratio [OR]_{duplex/triple} = 0.47–0.66). However, in patients with MEC, only aprepitant-based triple regimen showed better effect than duplex regimen statistically significantly in CRs (OR_{duplex/triple} = 0.52, 95% confidence interval [CI] = 0.34 to 0.68). No statistically significant difference of TRAEs was found among different triple regimens. Palonosetron-based triple regimens were equivalent to first-generation 5HT3RAs-based triple regimens for CRs. Moreover, different doses of dexamethasone plus NK-1RA and 5HT3RA showed no statistically significant difference in CRs.

Conclusions: Different NK-1RAs-based triple regimens shared equivalent effect on CINV control. Various triple regimens had superior antiemetic effect than duplex regimen in patients with HEC. Only aprepitant-based triple regimen showed better CINV control compared with duplex regimen in patients receiving MEC. Palonosetron and first-generation 5HT3RAs might share equivalent CINV control in the combination of NK-1RAs and dexamethasone. Lower doses of dexamethasone might be applied when used with NK-1RAs and 5HT3RAs.

http://ift.tt/2f7jP4q

Vitamin B6 and Cancer Risk: A Field Synopsis and Meta-Analysis

Background: Vitamin B6 is involved in many biochemical reactions and might play a role in carcinogenesis. We summarized the evidence linking vitamin B6 to cancer risk.

Methods: We conducted a systematic review of both observational and intervention studies investigating the relationship between vitamin B6 intake or blood levels of its bioactive form pyridoxal-5'-phosphate (PLP) and the risk of any type of cancer. Random-effects meta-analysis was used to calculate pooled relative risks (RRs) and their 95% confidence intervals (CIs) across studies for high vs low categories of vitamin intake or PLP levels. We also performed a random-effects dose-response meta-analysis.

Results: We identified 121 observational studies (participants, n = 1 924 506; cases, n = 96_,436) and nine randomized controlled trials (RCTs; participants, n = 34 911; cases, n = 2539) considering 19 tumor sites. High intake of dietary (food only) vitamin B6 was statistically significantly associated with lower risk of all cancers (relative risk [RR] = 0.78, 95% CI = 0.73 to 0.84) and specific tumors, with special regard to gastrointestinal carcinomas (RR = 0.68, 95% CI = 0.61 to 0.75). An inverse association was also observed between high PLP levels and the risk of all cancers (RR = 0.66, 95% CI = 0.58 to 0.76) and single tumor sites, the most consistent results being those for gastrointestinal tumors (RR = 0.56, 95% CI = 0.48 to 0.65). There was a statistically significant inverse linear relationship between cancer risk and both vitamin B6 dietary intake and PLP levels. When total (food and supplements) intake was considered, the associations were weaker or null. Findings from RCTs did not support a protective effect of vitamin B6 against cancer, although this evidence was graded as low level.

Conclusions: Epidemiological evidence supports the potential of vitamin B6 as a cancer risk reduction agent and the role of PLP as a cancer screening biomarker, especially for gastrointestinal tumors. However, inconsistent findings from total intake and intervention studies suggest that vitamin B6 might also be an indicator of other dietary protective micronutrients.

from Cancer via ola Kala on Inoreader http://ift.tt/2ecHDpT
via IFTTT

Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis

Background: Neurokinin-1 receptor antagonists (NK-1RAs) are widely used for chemotherapy-induced nausea and vomiting (CINV) control in patients with highly emetogenic chemotherapy (HEC) and/or moderately emetogenic chemotherapy (MEC). Whether the efficacy and toxicity of antiemesis are different among various NK-1RA-based triple regimens is unknown.

Methods: Data of complete responses (CRs) in the acute, delayed, and overall phases and treatment-related adverse events (TRAEs) were extracted from electronic databases. Efficacy and toxicity were integrated by pairwise and network meta-analyses.

Results: Thirty-six trials involving 18 889 patients using triple regimens (NK-1RA+serotonin receptor antagonists [5HT3RA] + dexamethasone) or duplex regimen (5HT3RA+dexamethasone) to control CINV were included in the analysis. Different NK-1RA-based triple regimens shared equivalent effect on CRs. In patients with HEC, almost all triple regimens showed statistically significantly higher CRs than duplex regimen (odds ratio [OR]_{duplex/triple} = 0.47–0.66). However, in patients with MEC, only aprepitant-based triple regimen showed better effect than duplex regimen statistically significantly in CRs (OR_{duplex/triple} = 0.52, 95% confidence interval [CI] = 0.34 to 0.68). No statistically significant difference of TRAEs was found among different triple regimens. Palonosetron-based triple regimens were equivalent to first-generation 5HT3RAs-based triple regimens for CRs. Moreover, different doses of dexamethasone plus NK-1RA and 5HT3RA showed no statistically significant difference in CRs.

Conclusions: Different NK-1RAs-based triple regimens shared equivalent effect on CINV control. Various triple regimens had superior antiemetic effect than duplex regimen in patients with HEC. Only aprepitant-based triple regimen showed better CINV control compared with duplex regimen in patients receiving MEC. Palonosetron and first-generation 5HT3RAs might share equivalent CINV control in the combination of NK-1RAs and dexamethasone. Lower doses of dexamethasone might be applied when used with NK-1RAs and 5HT3RAs.

from Cancer via ola Kala on Inoreader http://ift.tt/2f7jP4q
via IFTTT

Local Failure and Acute Radiodermatological Toxicity in Patients Undergoing Radiotherapy With and Without Post-Mastectomy Chest Wall Bolus: Is Bolus Ever Necessary?

Publication date: Available online 30 October 2016
Source:Practical Radiation Oncology
Author(s): Stephen Abel, Paul Renz, Mark Trombetta, Michael Cowher, E D Werts, Thomas B Julian, Rodney Wegner
PurposePost-mastectomy chest wall radiotherapy has historically used bolus to increase dose at the skin surface. Despite the theoretical benefits of bolus, the clinical implications of locoregional tumor control, cosmesis, and the incidence of radiodermatitis, are less well characterized. We hypothesized that treatment in the presence or absence of bolus results in equivalent chest wall recurrence rates but its presence results in more severe acute dermatologic toxicity.Methods and MaterialsLocally advanced breast cancer patients undergoing chest wall radiotherapy were retrospectively reviewed from 2005–2015 (n=106; 53 with bolus, 53 without). Outcomes including local failure, acute skin toxicity, and treatment interruptions were recorded.Median age was 59years (range 28–91) and median follow-up was 34months. Histology was invasive ductal carcinoma (73%), invasive lobular carcinoma (20%), inflammatory (6%) and neuroendocrine (1%). Fifty-nine percent were T3/T4 primary tumors and 29.2% had clinical/pathologic skin involvement. Node positive patients accounted for 80.2%. Chemotherapy was administered in 84.0%. All patients had 3-D conformal radiotherapy and received a median dose of 61Gy (range 50–63Gy).ResultsLocal failure was 6.6% (n=7) overall, with four failures in the bolus group and three in the no bolus group. No pathological factors were associated with local failure. Acute grade 2 and 3 skin toxicities (37 versus 22), and treatment interruptions (20 versus 3) were more common in the bolus group (p<0.05). Mean treatment interruption (14.5 versus 5days) was longer for patients receiving bolus. Patients undergoing treatment interruption were more likely to fail locally than patients not requiring a treatment interruption (17.4% versus 3.6%, p=0.0322).ConclusionsBolus omission in adjuvant chest wall radiotherapy may be a reasonable approach to avoid acute skin toxicity and treatment interruptions while preserving local control, however, further study will be needed to reach a definitive conclusion.



from Cancer via ola Kala on Inoreader http://ift.tt/2fuxbft
via IFTTT

Assessing Long Term Complications in Patients Undergoing Immediate Postmastectomy Breast Reconstruction and Adjuvant Radiation

Publication date: Available online 30 October 2016
Source:Practical Radiation Oncology
Author(s): R. Sacotte, N. Fine, J.Y. Kim, M. Alghoul, K. Bethke, N. Hansen, S.A. Khan, S. Kulkarni, J. Strauss, J. Hayes, E.D. Donnelly
PurposeTo report the long-term rate and timing of complications associated with postmastectomy radiation therapy (PMRT) following immediate breast reconstruction in a large patient population.Materials/MethodsWe identified and reviewed the charts of all patients with stage I-IIIC breast cancer who underwent mastectomy with immediate reconstruction followed by subsequent radiation therapy between November 1997 and May 2010. We aimed to assess the rate of major complications, defined as events requiring a separate and distinct procedure. Statistical analysis between variables was evaluated using Fisher's exact test and Pearson's Chi-Squared test.ResultsIn total, 134 patients met inclusion criteria having adequate long-term follow-up and documentation. The median follow-up for all patients was 77.4months (range 6–185months). The overall major complication rate was found to be 44%. Nine patients (6.7%) experienced complications for which a secondary procedure could not be performed to retain a reconstructed breast. The average time between initiation of PMRT and the first major complication was 13.5months, with 68.3% of first major complications occurring within 1year of PMRT initiation and 81.7% within 2years. The difference in incidence of major complications for patients undergoing immediate tissue expander/implant (TE/I) reconstruction followed by PMRT was not statistically different when compared to patients with immediate autologous tissue reconstruction (ATR) followed by PMRT (47.3% vs 30.4%, p=0.168).ConclusionThe risk of first major complications and reconstruction loss in patients undergoing PMRT on immediately reconstructed breasts is greatest within 1year of beginning radiation therapy and decreases significantly with time. Immediate autologous tissue reconstruction followed by PMRT can be performed with reasonable complication rates.



from Cancer via ola Kala on Inoreader http://ift.tt/2e2wFzU
via IFTTT

Local Failure and Acute Radiodermatological Toxicity in Patients Undergoing Radiotherapy With and Without Post-Mastectomy Chest Wall Bolus: Is Bolus Ever Necessary?

Publication date: Available online 30 October 2016
Source:Practical Radiation Oncology
Author(s): Stephen Abel, Paul Renz, Mark Trombetta, Michael Cowher, E D Werts, Thomas B Julian, Rodney Wegner
PurposePost-mastectomy chest wall radiotherapy has historically used bolus to increase dose at the skin surface. Despite the theoretical benefits of bolus, the clinical implications of locoregional tumor control, cosmesis, and the incidence of radiodermatitis, are less well characterized. We hypothesized that treatment in the presence or absence of bolus results in equivalent chest wall recurrence rates but its presence results in more severe acute dermatologic toxicity.Methods and MaterialsLocally advanced breast cancer patients undergoing chest wall radiotherapy were retrospectively reviewed from 2005–2015 (n=106; 53 with bolus, 53 without). Outcomes including local failure, acute skin toxicity, and treatment interruptions were recorded.Median age was 59years (range 28–91) and median follow-up was 34months. Histology was invasive ductal carcinoma (73%), invasive lobular carcinoma (20%), inflammatory (6%) and neuroendocrine (1%). Fifty-nine percent were T3/T4 primary tumors and 29.2% had clinical/pathologic skin involvement. Node positive patients accounted for 80.2%. Chemotherapy was administered in 84.0%. All patients had 3-D conformal radiotherapy and received a median dose of 61Gy (range 50–63Gy).ResultsLocal failure was 6.6% (n=7) overall, with four failures in the bolus group and three in the no bolus group. No pathological factors were associated with local failure. Acute grade 2 and 3 skin toxicities (37 versus 22), and treatment interruptions (20 versus 3) were more common in the bolus group (p<0.05). Mean treatment interruption (14.5 versus 5days) was longer for patients receiving bolus. Patients undergoing treatment interruption were more likely to fail locally than patients not requiring a treatment interruption (17.4% versus 3.6%, p=0.0322).ConclusionsBolus omission in adjuvant chest wall radiotherapy may be a reasonable approach to avoid acute skin toxicity and treatment interruptions while preserving local control, however, further study will be needed to reach a definitive conclusion.



http://ift.tt/2fuxbft

Assessing Long Term Complications in Patients Undergoing Immediate Postmastectomy Breast Reconstruction and Adjuvant Radiation

Publication date: Available online 30 October 2016
Source:Practical Radiation Oncology
Author(s): R. Sacotte, N. Fine, J.Y. Kim, M. Alghoul, K. Bethke, N. Hansen, S.A. Khan, S. Kulkarni, J. Strauss, J. Hayes, E.D. Donnelly
PurposeTo report the long-term rate and timing of complications associated with postmastectomy radiation therapy (PMRT) following immediate breast reconstruction in a large patient population.Materials/MethodsWe identified and reviewed the charts of all patients with stage I-IIIC breast cancer who underwent mastectomy with immediate reconstruction followed by subsequent radiation therapy between November 1997 and May 2010. We aimed to assess the rate of major complications, defined as events requiring a separate and distinct procedure. Statistical analysis between variables was evaluated using Fisher's exact test and Pearson's Chi-Squared test.ResultsIn total, 134 patients met inclusion criteria having adequate long-term follow-up and documentation. The median follow-up for all patients was 77.4months (range 6–185months). The overall major complication rate was found to be 44%. Nine patients (6.7%) experienced complications for which a secondary procedure could not be performed to retain a reconstructed breast. The average time between initiation of PMRT and the first major complication was 13.5months, with 68.3% of first major complications occurring within 1year of PMRT initiation and 81.7% within 2years. The difference in incidence of major complications for patients undergoing immediate tissue expander/implant (TE/I) reconstruction followed by PMRT was not statistically different when compared to patients with immediate autologous tissue reconstruction (ATR) followed by PMRT (47.3% vs 30.4%, p=0.168).ConclusionThe risk of first major complications and reconstruction loss in patients undergoing PMRT on immediately reconstructed breasts is greatest within 1year of beginning radiation therapy and decreases significantly with time. Immediate autologous tissue reconstruction followed by PMRT can be performed with reasonable complication rates.



http://ift.tt/2e2wFzU

"Anticancer Res"[jour]; +74 new citations

74 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results:

"Anticancer Res"[jour]

These pubmed results were generated on 2016/10/30

PubMed comprises more than 24 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

from Cancer via ola Kala on Inoreader http://ift.tt/2futqX7
via IFTTT

Effects of Jiaotaiwan on depressive-like behavior in mice after lipopolysaccharide administration

Abstract

Jiao-Tai-Wan (JTW), has been usually used for insomnia in traditional Chinese medicine (TCM). The previous study shown that JTW was benefit for depression-like behavior, but the possible mechanism is not clear. This study is to determine whether JTW was benefit for the treatment of lipopolysaccharide (LPS)-induced depression-like behavior in mice and explore its possible mechanism. All drugs were intragastrically administered once daily for 7 consecutive days. On the 7th day, LPS was injected into mice 30 min after drug administration. Behavioral tests were performed 24 h after LPS administration. Serum levels of interleukin (IL)-6 and tumor necrosis factor (TNF)-α were measured by enzyme-linked immunosorbent assay (ELISA). The 5-hydroxytryptamine (5-HT) and nor-epinephrine (NE) levels in prefrontal cortex were determined by UPLC-MS. The protein expressions of NF-κB signaling in prefrontal cortex were determined by western blot. Behavioral tests were measured via tail suspension test (TST), forced swimming test (FST), sucrose preference test (SPT) and open field test (OFT). In addition, effects of JTW on the TNF-α induced depressive-like behavior were also examined. Pretreatment with JTW (4.2 and 8.4 g/kg) or fluoxetine (20 mg/kg) effectively attenuated LPS-induced upregulations of the serum TNF-α and IL-6 contents and JTW (4.2 and 8.4 g/kg) or fluoxetine (20 mg/kg) effectively increased the contents of 5-HT and NE compared with LPS-treated group. Meanwhile, the western blot analysis results indicated the correlation between the antidepressant activity of JTW and the regulation of NF-κB signaling in brain. Besides, JTW (4.2 and 8.4 g/kg) or fluoxetine (20 mg/kg) significantly shortened LPS-induced increases in immobility time of TST, FST and weakened the reduction of the sucrose preference in SPT without significant alterations of locomotor activity in OFT. Additionally, JTW effectively reversed the depressive-like behavior induced by TNF-α (0.1 fg/site, i.c.v.). Our findings indicated that Jiao-Tai-Wan (JTW) played an important role in monoaminergic response and anti-inflammation in lipopolysaccharide (LPS)-induced mouse model, which may be therapeutically exploited to alleviate depression-like behavior.

http://ift.tt/2fu8Mq5

Effects of Jiaotaiwan on depressive-like behavior in mice after lipopolysaccharide administration

Abstract

Jiao-Tai-Wan (JTW), has been usually used for insomnia in traditional Chinese medicine (TCM). The previous study shown that JTW was benefit for depression-like behavior, but the possible mechanism is not clear. This study is to determine whether JTW was benefit for the treatment of lipopolysaccharide (LPS)-induced depression-like behavior in mice and explore its possible mechanism. All drugs were intragastrically administered once daily for 7 consecutive days. On the 7th day, LPS was injected into mice 30 min after drug administration. Behavioral tests were performed 24 h after LPS administration. Serum levels of interleukin (IL)-6 and tumor necrosis factor (TNF)-α were measured by enzyme-linked immunosorbent assay (ELISA). The 5-hydroxytryptamine (5-HT) and nor-epinephrine (NE) levels in prefrontal cortex were determined by UPLC-MS. The protein expressions of NF-κB signaling in prefrontal cortex were determined by western blot. Behavioral tests were measured via tail suspension test (TST), forced swimming test (FST), sucrose preference test (SPT) and open field test (OFT). In addition, effects of JTW on the TNF-α induced depressive-like behavior were also examined. Pretreatment with JTW (4.2 and 8.4 g/kg) or fluoxetine (20 mg/kg) effectively attenuated LPS-induced upregulations of the serum TNF-α and IL-6 contents and JTW (4.2 and 8.4 g/kg) or fluoxetine (20 mg/kg) effectively increased the contents of 5-HT and NE compared with LPS-treated group. Meanwhile, the western blot analysis results indicated the correlation between the antidepressant activity of JTW and the regulation of NF-κB signaling in brain. Besides, JTW (4.2 and 8.4 g/kg) or fluoxetine (20 mg/kg) significantly shortened LPS-induced increases in immobility time of TST, FST and weakened the reduction of the sucrose preference in SPT without significant alterations of locomotor activity in OFT. Additionally, JTW effectively reversed the depressive-like behavior induced by TNF-α (0.1 fg/site, i.c.v.). Our findings indicated that Jiao-Tai-Wan (JTW) played an important role in monoaminergic response and anti-inflammation in lipopolysaccharide (LPS)-induced mouse model, which may be therapeutically exploited to alleviate depression-like behavior.

from Cancer via ola Kala on Inoreader http://ift.tt/2fu8Mq5
via IFTTT